MedTrace Logo

Video-oculography and Parkinson's Disease

NCT04731246 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2025-10-01

No results posted yet for this study

Summary

This study aims to study, in patient with Parkinson's disease, mild to moderate stage (according to Movement Disorder Society Clinical Diagnostic Criteria for Parkinson's Disease, Postuma et al., 2015):

* the evolution of oculomotricity markers over time.
* the correlation between neurological evaluations (motor and non-motor scores), neuropsychological evaluations (cognitive disorders) and oculomotricity evaluation, over a follow-up period of 7 years.
* the impact of antiparkinsonian drugs on the evolution of oculomotricity assessment by video-oculography.
* the value of oculomotricity assessment by video-oculography as an evolutionary marker of the disease.

Conditions

  • Parkinson Disease, Idiopathic

Interventions

OTHER

Video-oculography / Neuropsychological evaluations

Annual evaluation: Medical history; Clinical, Neurological and Neuropsychological evaluations; Video-oculography examination; Inventory of examinations carried out in routine care (brain MRI, cerebral DaTScan, cerebral F-Dopa PET/CT scan, MIBG myocardial scintigraphy, blood test). Follow-up is carried out over 7 years.

Sponsors & Collaborators

  • Centre Hospitalier Princesse Grace

    collaborator OTHER

  • Centre Hospitalier Universitaire de Nice

    collaborator OTHER

  • Association de Recherche Bibliographique pour les Neurosciences

    lead OTHER

Principal Investigators

  • Philippe BARRES, MD · Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco.

  • Sandrine LOUCHART DE LA CHAPELLE, MD-PHD · Centre Mémoire, Centre de Gérontologie Clinique RAINIER III, Princess Grace Hospital, Monaco

  • Alain PESCE, PUPH · AREBISN (Association de Recherche Bibliographique pour les Neurosciences), Nice (France)

  • Caroline GIORDANA, MD · Centre Expert Parkinson, Unités des Pathologies du Mouvement, Hôpital Pasteur 2, Nice (France)

  • Benoit PAULMIER, MD · Médecine Nucléaire, Princess Grace Hospital, Monaco.

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-07-07
Primary Completion
2032-01-31
Completion
2032-01-31

Countries

  • Monaco

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04731246 on ClinicalTrials.gov